Posttranscription regulation of prostate cancer growth

Cancer Journal

Volumn 14, Issue 1, 2008, Pages 46-53

  Shen, Li ^a   Pili, Roberto ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Clinical development; Histone deacetylase inhibitors; mRNA targeting; Prostate cancer; Protein modification

Indexed keywords

3 PHENYLSULFAMOYLCINNAMOHYDROXAMIC ACID; 4 [N (2 HYDROXYETHYL) N [2 (3 INDOLYL)ETHYL]AMINOMETHYL]CINNAMOHYDROXAMIC ACID; ANTISENSE OLIGONUCLEOTIDE; BEVACIZUMAB; CLUSTERIN; DEPSIPEPTIDE; DOCETAXEL; HEAT SHOCK PROTEIN 90 INHIBITOR; HISTONE DEACETYLASE INHIBITOR; ISOTRETINOIN; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; MIDOSTAURIN; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; N (2 AMINOPHENYL) 4 [4 (3 PYRIDINYL) 2 PYRIMIDINYLAMINOMETHYL]BENZAMIDE; OBLIMERSEN; OGX 011; PANOBINOSTAT; PHOSPHATIDYLINOSITOL 3 KINASE; POLYCOMB GROUP PROTEIN; PROTEIN BCL XL; SMALL INTERFERING RNA; SNDX 275; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TRICHOSTATIN A; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VASCULOTROPIN; VATALANIB; VORINOSTAT; ANTINEOPLASTIC AGENT; BCL2L1 PROTEIN, HUMAN; DNA BINDING PROTEIN; ENZYME INHIBITOR; EZH2 PROTEIN, HUMAN; HISTONE DEACETYLASE; PROTEIN BCL X; PROTEIN SYNTHESIS INHIBITOR; TRANSCRIPTION FACTOR; VASCULOTROPIN A;

ANOREXIA; ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER RESISTANCE; CANCER SURGERY; CLINICAL TRIAL; COLON CARCINOMA; DEHYDRATION; DIARRHEA; DRUG BIOAVAILABILITY; FATIGUE; GENE CONTROL; GENE TARGETING; HUMAN; KIDNEY CARCINOMA; LYMPHOCYTOPENIA; METASTASIS; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN SYNTHESIS; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; SIGNAL TRANSDUCTION; T CELL LYMPHOMA; TRANSCRIPTION REGULATION; UNSPECIFIED SIDE EFFECT; DISEASE COURSE; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; MALE; METABOLISM; PATHOPHYSIOLOGY; PROSTATE TUMOR; PROTO ONCOGENE;

ANTINEOPLASTIC AGENTS; BCL-X PROTEIN; CLUSTERIN; DISEASE PROGRESSION; DNA-BINDING PROTEINS; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, BCL-2; HISTONE DEACETYLASES; HUMANS; MALE; PROSTATIC NEOPLASMS; PROTEIN SYNTHESIS INHIBITORS; RNA, MESSENGER; TRANSCRIPTION FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 43049170370     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e318162108a     Document Type: Review

References (63)

1. Coppelli FM, Grandis JR. Oligonucleotides as anticancer agents: from the benchside to the clinic and beyond. Curr Pharm Des. 2005;11:2825-2840.
2. Hede K. New: Blocking cancer with RNA interference moves toward the clinic. J Natl Cancer Inst. 2005;97:626-628.
3. Pienta KJ. Preclinical mechanisms of action of docetaxel and docetaxel combinations in prostate cancer. Semin Oncol. 2001;28(4 Suppl 15):3-7.
4. Zhang H, Kim JK, Edwards CA, et al. Clusterin inhibits apoptosis by interacting with activated Bax. Nat Cell Biol. 2005;7:909-915.
5. Bruchovsky N, Snoek R, Rennie PS, et al. Control of tumor progression by maintenance of apoptosis. Prostate Suppl. 1996;6:13-21.
6. Gleave M, Jansen B. Clusterin and IGFBPs as antisense targets in prostate cancer. Ann NY Acad Sci. 2003;1002:95-104.
7. Devi GR. XIAP as target for therapeutic apoptosis in prostate cancer. Drug News Perspect. 2004;17:127-134.
8. Bianco R, Ciardiello F, Tortora G. Chemosensitization by antisense oligonucleotides targeting MDM2. Curr Cancer Drug Targets. 2005;5: 51-56.
9. Keller ET, Fu Z, Brennan M. The role of Raf kinase inhibitor protein (RKIP) in health and disease. Biochem Pharmacol. 2004;68:1049-1053.
10. Chi KN, Eisenhauer E, Fazli L, et al. A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2′-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J Natl Cancer Inst. 2005;97:1287-1296.
11. Varambally S, Dhanasekaran SM, Zhou M, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature. 2002;419:624-629.
12. Takeshita F, Minakuchi Y, Nagahara S, et al. Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo. Proc Natl Acad Sci USA. 2005;102:12177-12182.
13. George DJ, Halabi S, Shepard TF, et al. Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res. 2001;7:1932-1936.
14. Benjamin LE, Golijanin D, Itin A, et al, Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest. 1999;103:159-165.
15. Franck-Lissbrant I, Häggström S, Damber J-E, et al. Testosterone has been shown to stimulate angiogenesis and vascular regrowth in the ventral prostate in castrated rats. Endocrinology. 1998;139:451-456.
16. Silberman MA, Partin AW, Veltri RW, et al. Tumor angiogenesis correlates with progression after radical prostatectomy but not with pathologic stage in Gleason sum 5 to 7 adenocarcinoma of the prostate. Cancer. 1997;79:772-779.
17. Brown LF, Yeo KT, Berse B, et al. Vascular permeability factor (vascular endothelial growth factor) is strongly expressed in the normal male genital tract and is present in substantial quantities in semen. J Urol. 1995;154:576-579.
18. George DJ, Regan MM, Oh WK, et al. Radical prostatectomy lowers plasma vascular endothelial growth factor levels in patients with prostate cancer. Urology. 2004;63:327-332.
19. Takei Y, Kadomatsu K, Yuzawa Y, et al. A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics. Cancer Res. 2004;64:3365-3370.
20. Low WK, Dang Y, Schneider-Poetsch T, et al. Inhibition of eukaryotic translation initiation by the marine natural product pateamine A. Mol Cell. 2005;20:709-722.
21. Graff JR, Konicek BW, Vincent TM, et al. Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity. J Clin Invest. 2007;117:2638-2648.
22. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism Cell. 2006;124:471-484.
23. Kouzarides T. Histone acetylases and deacetylases in cell proliferation. Curr Opin Genet Dev. 1999;9:40-48.
24. Johnstone RW, Licht JD. Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell. 2003;4:13-18.
25. Marks PA, Richon VM, Miller T. et al. Histone deacetylases inhibitors. Adv. Cancer Res. 2004;91:137-168.
26. Marks OA, Rifkind RA, Richon VM, et al. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer. 2001;1:194-202.
27. Agalioti T, Chen G, Thanos D. Deciphering the transcriptional histone acetylation code for a human gene Cell. 2002;111:381-392.
28. Jung M, Velena A, Chen B, et al. Novel HDAC inhibitors with radiosensitizing properties. Radiat Res. 2005;163:488-493.
29. Qian DZ, Ren M, Wei Y, et al. In vivo imaging of retinoic acid receptor beta2 transcriptional activation by the histone deacetylase inhibitor MS-275 in retinoid-resistant prostate cancer cells. Prostate. 2005;64: 20-28.
30. Marchion DC, Bicaku E, Daud AI, et al. Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid. J Cell Biochem. 2004;92:223-237.
31. Nimmanapalli R, Fuino L, Bali P, et al. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells. Cancer Res. 2003;63:5126-5135.
32. Fuino L, Bali P, Wittmann S, et al. Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, Taxotere, gemcitabine, and epothilone B. Mol Cancer Ther. 2003;2:971-984.
33. Bali P, George P, Cohen P, et al. Superior activity of the combination of histone deacetylase inhibitor LAQ824 and the FLT-3 kinase inhibitor PKC412 against human acute myelogenous leukemia cells with mutant FLT-3. Clin Cancer Res. 2004;1:4991-4997.
34. Rosato RR, Almenara JA, Dai Y, Grant S. Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells. Mol Cancer Ther. 2003;2:1273-1284.
35. + cells sensitive and resistant to STI571. Blood. 2003;102:3765-3774.
36. Maggio SC, Rosato RR, Kramer LB, et al. The histone deacetylase inhibitor MS-275 interacts synergistically with fludarabine to induce apoptosis in human leukemia cells. Cancer Res. 2004;64:2590-2600.
37. + cells sensitive and resistant to STI571 (imatinib mesylate) in association with down-regulation of Bcr-Abl, abrogation of signal transducer and activator of transcription 5 activity, and Bax conformational change. Mol Pharmacol. 2005;67: 1166-1176.
38. Glozak MA, Sengupta N, Zhang X, et al. Acetylation and deacetylation of non-histone proteins. Gene. 2005;363:15-23.
39. Blagosklonny MV, Trostel S, Kayastha G, et al. Depletion of mutant p53 and cytotoxicity of histone deacetylase inhibitors. Cancer Res. 2005;65: 7386-7392.
40. Aoyagi S, Archer TK. Modulating molecular chaperone Hsp90 functions through reversible acetylation. Trends Cell Biol. 2005;15:565-567.
41. Chen L, Meng S, Wang H, et al. Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824. Mol Cancer Ther. 2005;4:1311-1319.
42. Chen CS, Weng SC, Tseng PH, et al. Histone acetylation-independent effect of histone deacetylase inhibitors on Akt through the reshuffling of protein phosphatase 1 complexes. JBiol Chem. 2005;280:38879-38887.
43. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182-1186.
44. Holash J, Wiegand SJ, Yancopoulos GD. New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. Oncogene. 1999;18:5356-5362.
45. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003;3:721-732.
46. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature. 2005;438:967-974.
47. Hurwitz H, Fehrenbacher L, Cartwright T, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342.
48. Escudier B, Szczylik C, Eisen T, et al. Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). J Clin Oncol. 2005;23(16 suppl):4510.
49. Motzer RJ, Rini BI, Michaelson MD, et al. Phase 2 trials of SU11248 show antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma (RCC). J Clin Oncol. 2005;23(16 suppl): 4508.
50. Qian DZ, Wang X, Kachhap SK, et al. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584. Cancer Res. 2004;64:6626-6634.
51. Qian DZ, Kachhap SK, Collis SJ, et al. Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 α. Cancer Res. 2006;66:8814-8821.
52. Kelly WK, Marks PA. Drug insight: histone deacetylase inhibitors - development of the new targeted anticancer agent suberoylanilide hydroxamic acid. Nat Clin Pract Oncol. 2005;2:150-157.
53. Kelly WK, Richon VM, O'Connor O, et al. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res. 2003;9(10 pt 1):3578-3588.
54. Kelly WK, O'Connor OA, Krug LM, et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol. 2005;23:3923-3931.
55. O'Connor OA, Heaney ML, Schwartz L, et al. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol. 2006;24:166-173.
56. Duvic M, Talpur C, Zhang A, et al. Phase II trial of oral suberoylanilide hydroxamic acid (SAHA) for cutaneous T-cell lymphoma (CTCL) unresponsive to conventional therapy. J Clin Oncol. 2005;(16 suppl): 6571.
57. Kummar S, Gutierrez M, Gardner ER, et al. Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies. Clin Cancer Res. 2007;13(18 pt 1): 5411-5417.
58. Piekarz RL, Robey RW, Zhan Z, et al. T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance. Blood. 2004;103:4636-4643.
59. Giles F, Fischer T, Cortes J, et al. A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res. 2006;12:4628-4635.
60. Kelly WK, Yap T, Lee J, et al. A phase I study of oral belinostat (PXD101) in patients with advanced solid tumors. J Clin Oncol. 2005; 25(18 suppl):14092.
61. Carducci M, Siu LL, Sullivan R, et al. Phase I study of isotype-selective stone deacetylase (HDAC inhibitor MGCD0103 given as three-times weekly oral dose in patients (pts) with advanced solid tumors. J Clin Oncol. 2005;25(18 suppl):3007.
62. Carducci MA, Gilbert J, Bowling MK, et al. A phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule. Clin Cancer Res. 2001;7:3047-3055.
63. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer. 2006;6: 38-51.